Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B

研究成果: Article

9 引文 (Scopus)

摘要

Background: Despite its recognized role as a prognostic marker for antiviral treatment, the clinical significance of serum hepatitis B surface antigen (HBsAg) level in the immune-clearance stage of chronic hepatitis B remains unclear. Objectives: To characterize how HBsAg level and various clinical and virological factors are related and analyze the correlation of HBsAg with liver histology. Study design: A total of 198 treatment-naïve HBeAg-positive chronic hepatitis B patients were enrolled. Serum HBV DNA and HBsAg were determined quantitatively. Mutations of precore or basal core promoter (BCP) were also determined. Finally, liver necroinflammation grading and fibrosis stage were evaluated by Knodell score and Ishak score, respectively. Results: Lower HBsAg levels were found in patients with genotype C HBV infection, or in the presence of precore or mutations, or Knodell necroinflammation grading ≥7, or advanced fibrosis (Ishak stage 4-6). HBsAg level displayed a strong correlation with HBV DNA ( r= 0.727, P<. 0.001) and also exhibited a positive correlation with intrahepatic HBcAg expression in either cytoplasm ( r= 0.420, P<. 0.001) or nucleus ( r= 0.401, P<. 0.001). Examining the correlation with advanced liver fibrosis revealed that HBsAg level is a significant factor in univariate analysis and is the only independent factor in multivariate analysis (Coefficient: -0.975, P= 0.039, OR: 0.377, 95% CI: 0.149-0.953). Conclusions: HBsAg level varied with different clinical or virological categories. Lower baseline levels of HBsAg might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B patients.

原文English
頁(從 - 到)323-330
頁數8
期刊Journal of Clinical Virology
57
發行號4
DOIs
出版狀態Published - 2013 八月 1

指紋

Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B Surface Antigens
Histology
Liver
Serum
Liver Cirrhosis
Fibrosis
Hepatitis B Core Antigens
Mutation
DNA
Statistical Factor Analysis
Antiviral Agents
Cytoplasm
Multivariate Analysis
Genotype

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

引用此文

@article{ded9ed9463af4af0b647611462ae7125,
title = "Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B",
abstract = "Background: Despite its recognized role as a prognostic marker for antiviral treatment, the clinical significance of serum hepatitis B surface antigen (HBsAg) level in the immune-clearance stage of chronic hepatitis B remains unclear. Objectives: To characterize how HBsAg level and various clinical and virological factors are related and analyze the correlation of HBsAg with liver histology. Study design: A total of 198 treatment-na{\"i}ve HBeAg-positive chronic hepatitis B patients were enrolled. Serum HBV DNA and HBsAg were determined quantitatively. Mutations of precore or basal core promoter (BCP) were also determined. Finally, liver necroinflammation grading and fibrosis stage were evaluated by Knodell score and Ishak score, respectively. Results: Lower HBsAg levels were found in patients with genotype C HBV infection, or in the presence of precore or mutations, or Knodell necroinflammation grading ≥7, or advanced fibrosis (Ishak stage 4-6). HBsAg level displayed a strong correlation with HBV DNA ( r= 0.727, P<. 0.001) and also exhibited a positive correlation with intrahepatic HBcAg expression in either cytoplasm ( r= 0.420, P<. 0.001) or nucleus ( r= 0.401, P<. 0.001). Examining the correlation with advanced liver fibrosis revealed that HBsAg level is a significant factor in univariate analysis and is the only independent factor in multivariate analysis (Coefficient: -0.975, P= 0.039, OR: 0.377, 95{\%} CI: 0.149-0.953). Conclusions: HBsAg level varied with different clinical or virological categories. Lower baseline levels of HBsAg might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B patients.",
author = "Cheng, {Pin Nan} and Tsai, {Hung Wen} and Chiu, {Yen Cheng} and Ho, {Cheng Hsun} and Wu, {I. Chin} and Chang, {Ting Tsung}",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.jcv.2013.04.012",
language = "English",
volume = "57",
pages = "323--330",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B

AU - Cheng, Pin Nan

AU - Tsai, Hung Wen

AU - Chiu, Yen Cheng

AU - Ho, Cheng Hsun

AU - Wu, I. Chin

AU - Chang, Ting Tsung

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Despite its recognized role as a prognostic marker for antiviral treatment, the clinical significance of serum hepatitis B surface antigen (HBsAg) level in the immune-clearance stage of chronic hepatitis B remains unclear. Objectives: To characterize how HBsAg level and various clinical and virological factors are related and analyze the correlation of HBsAg with liver histology. Study design: A total of 198 treatment-naïve HBeAg-positive chronic hepatitis B patients were enrolled. Serum HBV DNA and HBsAg were determined quantitatively. Mutations of precore or basal core promoter (BCP) were also determined. Finally, liver necroinflammation grading and fibrosis stage were evaluated by Knodell score and Ishak score, respectively. Results: Lower HBsAg levels were found in patients with genotype C HBV infection, or in the presence of precore or mutations, or Knodell necroinflammation grading ≥7, or advanced fibrosis (Ishak stage 4-6). HBsAg level displayed a strong correlation with HBV DNA ( r= 0.727, P<. 0.001) and also exhibited a positive correlation with intrahepatic HBcAg expression in either cytoplasm ( r= 0.420, P<. 0.001) or nucleus ( r= 0.401, P<. 0.001). Examining the correlation with advanced liver fibrosis revealed that HBsAg level is a significant factor in univariate analysis and is the only independent factor in multivariate analysis (Coefficient: -0.975, P= 0.039, OR: 0.377, 95% CI: 0.149-0.953). Conclusions: HBsAg level varied with different clinical or virological categories. Lower baseline levels of HBsAg might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B patients.

AB - Background: Despite its recognized role as a prognostic marker for antiviral treatment, the clinical significance of serum hepatitis B surface antigen (HBsAg) level in the immune-clearance stage of chronic hepatitis B remains unclear. Objectives: To characterize how HBsAg level and various clinical and virological factors are related and analyze the correlation of HBsAg with liver histology. Study design: A total of 198 treatment-naïve HBeAg-positive chronic hepatitis B patients were enrolled. Serum HBV DNA and HBsAg were determined quantitatively. Mutations of precore or basal core promoter (BCP) were also determined. Finally, liver necroinflammation grading and fibrosis stage were evaluated by Knodell score and Ishak score, respectively. Results: Lower HBsAg levels were found in patients with genotype C HBV infection, or in the presence of precore or mutations, or Knodell necroinflammation grading ≥7, or advanced fibrosis (Ishak stage 4-6). HBsAg level displayed a strong correlation with HBV DNA ( r= 0.727, P<. 0.001) and also exhibited a positive correlation with intrahepatic HBcAg expression in either cytoplasm ( r= 0.420, P<. 0.001) or nucleus ( r= 0.401, P<. 0.001). Examining the correlation with advanced liver fibrosis revealed that HBsAg level is a significant factor in univariate analysis and is the only independent factor in multivariate analysis (Coefficient: -0.975, P= 0.039, OR: 0.377, 95% CI: 0.149-0.953). Conclusions: HBsAg level varied with different clinical or virological categories. Lower baseline levels of HBsAg might reflect the status of advanced liver fibrosis in HBeAg positive chronic hepatitis B patients.

UR - http://www.scopus.com/inward/record.url?scp=84879269775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879269775&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2013.04.012

DO - 10.1016/j.jcv.2013.04.012

M3 - Article

C2 - 23731848

AN - SCOPUS:84879269775

VL - 57

SP - 323

EP - 330

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 4

ER -